During the past decade, St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan" conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 12 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 10 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "R-Pharm International, LLC" with 3 trials sponsored, "Alexion" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Valenta Pharm JSC" with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 3 trials as a collaborator and "Mene Research" with 2 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Rheumatoid Arthritis" (3 trials), "Breast Neoplasms" (2 trials), "Influenza" (2 trials) and "Neuromyelitis Optica" (2 trials). Many other conditions were trialed in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"" in a lesser frequency.

Most popular intervention types in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"" are "Drug" (14 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Olokizumab" (2 trials), "Adalimumab 40mg q2w" (1 trials), "Afatinib 40mg once daily (OD)" (1 trials) and "Avastin" (1 trials). Other intervention names were less common.

The vast majority of trials in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"" are 13 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan", undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan", 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".